SKYE News and Press, Skye Bioscience Inc Com From 08/26/22

Emerald Health Therapeutics ( OTCQB:EMHTF ) said the Supreme Court of British Columbia approved the company's merger with Skye Bioscience ( OTCQB:SKYE ). In May, Canadian medical cannabis company Emerald and San Diego-based Skye announced a merger vi...

Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that on August 25, 2022, the Supreme Court of British Columbia issued a final order approving the Company's previously announc...

San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald...

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional background on its transaction (the "Transaction") with Skye Bioscience Inc. (OTCQB: SKYE) ("Skye...

Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company develop...

San Diego, California, July 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufac...

Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea SEOUL, S.KOREA, July 13, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK b...

Skye Bioscience ( OTCQB:SKYE ) said on Thursday it had received Australian regulatory approval to begin its first-in-human Phase 1 study of SBI-100 Ophthalmic Emulsion to treat glaucoma. The main goal of the study of SBI-100 are an assessment of safety and tolerabili...

Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studies San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical ...

New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company ...